Starry(SH:603520) Shang Hai Zheng Quan Bao·2026-01-30 23:15Core Viewpoint - Zhejiang Sitaili Pharmaceutical Co., Ltd. is expected to achieve a turnaround in net profit for the year 2025, projecting a net profit attributable to shareholders of 10 million to 13 million yuan, compared to a loss in the previous year [2][3]. Group 1: Performance Forecast - The performance forecast period is from January 1, 2025, to December 31, 2025 [3]. - The company anticipates a net profit attributable to shareholders of 10 million to 13 million yuan, indicating a significant improvement from the previous year's loss of 49.09 million yuan [2][6]. - The projected net profit after deducting non-recurring gains and losses is estimated to be between 2.5 million and 5.5 million yuan [4]. Group 2: Previous Year’s Performance - In the previous year, the total profit was -57.17 million yuan, with a net profit attributable to shareholders of -49.09 million yuan [6]. - The net profit after deducting non-recurring gains and losses was -54.13 million yuan, and the earnings per share were -0.12 yuan [7][6]. Group 3: Reasons for Profit Turnaround - The improvement in performance is attributed to an optimized revenue structure, with an increase in the sales proportion of high-margin products, alongside cost control measures such as process optimization and refined supply chain management [8]. - The company benefited from a decrease in financing costs due to a decline in the Loan Prime Rate (LPR) and proactive debt structure optimization, leading to a significant reduction in interest expenses [8]. - Additionally, foreign exchange gains from the company's foreign currency assets contributed to the decrease in financial expenses [8].